-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Elicio Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q2 2024.
- Elicio Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$10.9M, a 40.5% decline year-over-year.
- Elicio Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$41.3M, a 122% decline year-over-year.
- Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$35.7M, a 50.6% decline from 2022.
- Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$23.7M, a 39.6% increase from 2021.
- Elicio Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$39.3M, a 28.9% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)